Articles Tagged With:
-
Privacy Remains Central Problem with Genomic Data-Sharing
Making the system more trustworthy requires greater transparency, clear principles of accountability, and more comprehensive laws and regulations that protect against discriminatory uses of genetic information. The results of a recent survey may reveal the work ahead.
-
New Guidance Outlines Ethics of Embryo Research
According to the statement, human embryo research is ethically acceptable if it is “likely to provide significant new knowledge that may benefit human health, well-being of the offspring, or reproduction.”
-
Ethical Concerns About Surge of Involuntary Psychiatric Detention, Lack of Data
There is no national database on involuntary detentions. States and jurisdictions inconsistently report rates. States differ as to what label they use for detentions; whether they count events or unique persons; whether they report the age group (adult or child), sex, or ethnicity; whether the detention is short- or long-term; how long people are held; whether all eligible counties or institutions are reporting; who prepares the data; and time frames to release data.
-
Decisions on Family Observing Resuscitation Efforts Center on Autonomy, Beneficence
Ethicists can discuss underlying issues with clinicians proactively. They also can help develop clear, consistent policies on family-witnessed resuscitation.
-
Price Transparency: Ethicists Can Play a Role
Hospitals are devoting plenty of resources to the logistics of how they are going to comply with new federal price transparency requirements. There also are important ethical implications.
-
Consults Alone Do Not Give Full Ethics Picture: Much Work Goes Unacknowledged
Ethics services are finding that the number of consults requested does not tell the full story of their workload. Insiders share tips on how to quantify these duties.
-
A New Treatment for Refractory Hyperlipidemia
In patients with familial hypercholesterolemia who are not at target LDL cholesterol levels on maximum-tolerated doses of statins and PCSK9 inhibitors, evinacumab, which inhibits angiopoietin-like 3, reduces LDL by more than 50% at the highest doses with few side effects requiring drug discontinuation vs. placebo.
-
Expanding Uses for Direct Oral Anticoagulants: Bioprosthetic Heart Valves?
A randomized, controlled trial of rivaroxaban vs. warfarin in patients with atrial fibrillation and a bioprosthetic valve revealed rivaroxaban is noninferior to warfarin for the prevention of major cardiovascular events and the avoidance of major bleeding events over 12 months.
-
Time is of the Essence with Colchicine Treatment of Myocardial Infarction
An analysis of the COLCOT study of colchicine administration after myocardial infarction (MI) showed the benefit of this therapy for preventing subsequent cardiovascular events was greatest when therapy was initiated within three days after MI onset.
-
Left Ventricular Size, Function Predictors of Outcomes in Chronic Aortic Regurgitation
In a large cohort of asymptomatic patients with hemodynamically significant chronic aortic regurgitation, volumetric left ventricular size and function measurements were equally discriminant in identifying patients at higher risk for mortality vs. traditional linear measurements.